Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions
- PMID: 26282120
- DOI: 10.1016/j.neuropharm.2015.08.019
Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions
Abstract
The potential contributions of dysregulation of the brain's histaminergic modulatory system to neuropsychiatric disease, and the potential of histamine-targeting medications as therapeutic agents, are gradually coming into focus. The H3R receptor, which is expressed primarily in the central nervous system, is a promising pharmacotherapeutic target. Recent evidence for a contribution of histamine dysregulation to Tourette syndrome and tic disorders is particularly strong; although specific mutations in histamine-associated genes are rare, they have led to informative studies in animal models that may pave the way for therapeutic advances. A controlled study of an H3R antagonist in Tourette syndrome is ongoing. Preclinical studies of H3R antagonists in schizophrenia, attention deficit disorder, and narcolepsy have all shown promise. Recently reported controlled studies have been disappointing in schizophrenia and attention deficit disorder, but the H3R antagonist pitolisant shows promise in the treatment of narcolepsy and excessive daytime sleepiness and is currently under regulatory review for these conditions. This article is part of the Special Issue entitled 'Histamine Receptors'.
Keywords: H3 receptor; Histamine; Narcolepsy; Tourette syndrome.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases.Behav Brain Res. 2016 Oct 1;312:415-30. doi: 10.1016/j.bbr.2016.06.051. Epub 2016 Jun 27. Behav Brain Res. 2016. PMID: 27363923 Review.
-
Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences.Curr Neuropharmacol. 2022;20(2):403-411. doi: 10.2174/1570159X19666210909144930. Curr Neuropharmacol. 2022. PMID: 34521328 Free PMC article. Review.
-
The Histaminergic System in Neuropsychiatric Disorders.Biomolecules. 2021 Sep 11;11(9):1345. doi: 10.3390/biom11091345. Biomolecules. 2021. PMID: 34572558 Free PMC article. Review.
-
Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders.Handb Exp Pharmacol. 2017;241:259-276. doi: 10.1007/164_2016_125. Handb Exp Pharmacol. 2017. PMID: 28233178 Review.
-
Histamine H3 receptor antagonist decreases cue-induced alcohol reinstatement in mice.Neuropharmacology. 2016 Jul;106:156-63. doi: 10.1016/j.neuropharm.2015.06.006. Epub 2015 Jun 21. Neuropharmacology. 2016. PMID: 26107118
Cited by
-
4-Oxypiperidine Ethers as Multiple Targeting Ligands at Histamine H3 Receptors and Cholinesterases.ACS Chem Neurosci. 2024 Mar 20;15(6):1206-1218. doi: 10.1021/acschemneuro.3c00800. Epub 2024 Mar 5. ACS Chem Neurosci. 2024. PMID: 38440987 Free PMC article.
-
Sleep Disturbance in Tourette's Disorder: Potential Underlying Mechanisms.Curr Sleep Med Rep. 2023 Mar;9(1):10-22. doi: 10.1007/s40675-022-00242-5. Epub 2023 Jan 23. Curr Sleep Med Rep. 2023. PMID: 37636897 Free PMC article.
-
Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial.Chin Med. 2023 Apr 17;18(1):41. doi: 10.1186/s13020-023-00746-4. Chin Med. 2023. PMID: 37069570 Free PMC article.
-
The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors.J Biol Chem. 2023 Apr;299(4):104583. doi: 10.1016/j.jbc.2023.104583. Epub 2023 Mar 4. J Biol Chem. 2023. PMID: 36871761 Free PMC article.
-
Gut Barrier Dysfunction and Type 2 Immunity: Implications for Compulsive Behavior.Med Hypotheses. 2022 Apr;161:110799. doi: 10.1016/j.mehy.2022.110799. Epub 2022 Feb 14. Med Hypotheses. 2022. PMID: 36060122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical